Modulating gut microbiota to treat cancer
- 5 February 2021
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 371 (6529), 573-574
- https://doi.org/10.1126/science.abg2904
Abstract
Fecal microbiota transplantation is evaluated in melanoma patients resistant to immunotherapyThis publication has 11 references indexed in Scilit:
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patientsScience, 2021
- Current Evidence in Delivery and Therapeutic Uses of Fecal Microbiota Transplantation in Human Diseases-Clostridium difficile Disease and BeyondThe American Journal of the Medical Sciences, 2018
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisThe Lancet Oncology, 2018
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience, 2018
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience, 2018
- Intestinal Microbiota and Relapse After Hematopoietic-Cell TransplantationJournal of Clinical Oncology, 2017
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabJournal of Clinical Oncology, 2016
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacyScience, 2015
- Duodenal Infusion of Donor Feces for RecurrentClostridium difficileThe New England Journal of Medicine, 2013